Effects of platelet-rich plasma-containing fragmin/protamine microparticles in enhancing endothelial and smooth muscle cell growth and inducing collateral vessels in a rabbit model of hindlimb ischemia

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 101 B, Issue 1, 2013, Pages 36-42

  Fujita, Masanori ^a   Horio, Takuya ^a   Kishimoto, Satoko ^a,b   Nakamura, Shingo ^a   Takikawa, Megumi ^a   Nakayama, Takefumi ^a   Yamamoto, Yoritsuna ^a   Shimizu, Masafumi ^a   Hattori, Hidemi ^a   Tachibana, Shoichi ^a   Ishihara, Masayuki ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

controlled release; fragmin protamine microparticles (F P MPs); localized protein delivery; peripheral artery disease (PAD); platelet rich plasma (PRP)

Indexed keywords

CONTROLLED RELEASE; MICRO-PARTICLES; PERIPHERAL ARTERY DISEASE; PLATELET-RICH PLASMA; PROTEIN DELIVERY;

ENDOTHELIAL CELLS; PROTEINS;

PLASMA (HUMAN);

DALTEPARIN; PHOSPHATE BUFFERED SALINE; PROTAMINE;

ANGIOGENESIS; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CELL GROWTH; COLLATERAL CIRCULATION; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; FEMORAL ARTERY; FREEZE THAWING; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MALE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET MICROPARTICLE; RABBIT; SMOOTH MUSCLE FIBER; THROMBOCYTE RICH PLASMA;

ANIMALS; CELLS, CULTURED; DALTEPARIN; DISEASE MODELS, ANIMAL; HINDLIMB; ISCHEMIA; MALE; MICROSPHERES; MUSCLE, SMOOTH; PLATELET-RICH PLASMA; PROTAMINES; RABBITS;

EID: 84871366216     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32808     Document Type: Article

References (33)

1. Fadini GP, Agostini C, Avogaro A,. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209: 10-17.
2. Guidelines for percutaneous transluminal angioplasty. Standards of Practice Committee of the Society of Cardiovascular and Interventional Radiology. Radiology 1990; 177: 619-626.
3. Valentine RJ, Myers SI, Inman MH, Roberts JR, Clagett GP,. Late outcome of amputees with premature atherosclerosis. Surgery 1996; 119: 487-493. (Pubitemid 26141022)
4. Hiatt WR,. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621. (Pubitemid 32479915)
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG,; TASC II Working Group, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E III, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K,. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (suppl 1): S5-S67. (Pubitemid 46151680)
6. Ouriel K,. Peripheral arterial disease. Lancet 2001; 358: 1257-1264. (Pubitemid 33010855)
7. Carmeliet P,. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395. (Pubitemid 30208155)
8. Schaper W, Scholz D,. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 1143-1151. (Pubitemid 36871267)
9. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Giménez-Gallego G,. Hypotensive activity of fibroblast growth factor. Science 1991; 254: 1208-1210. (Pubitemid 21917455)
10. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W,. Stimulation of arteriogenesis: A new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 532-542.
11. Takikawa M, Nakamura S, Nakamura S, Nambu M, Ishihara M, Murakami K, Kishimoto S, Sasaki K, Yanagishita S, Azuma R, Yamamoto N, Kiyosawa T,. Stimulation of vascularization and granulation tissue formation by growth factors in human platelet-rich plasma (PRP) containing fragmin/protamine micro particles (F/P MPs). J Biomed Mater Res 2011; 97B: 373-380.
12. Marx RE,. Platelet-rich plasma (PRP): What is PRP and what is not PRP? Implant Dent 2001; 10: 225-228.
13. Bhanot S, Alex JC,. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg 2002; 18: 27-33. (Pubitemid 34133954)
14. Nakamura S, Kanatani Y, Kishimoto S, Nakamura S, Ohno C, Horio T, Masanori F, Hattori H, Tanaka Y, Kiyosawa T, Maehara T, Ishihara M,. Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization. J Biomed Mater Res A 2009; 91: 814-823.
15. Horio T, Fujita M, Tanaka Y, Ishihara M, Kishimoto S, Nakamura S, Hase K, Maehara T,. Efficacy of fragmin/protamine microparticles containing fibroblast growth factor-2 (F/P MPs/FGF-2) to induce collateral vessels in a rabbit model of hindlimb ischemia. J Vasc Surg 2011; 54: 791-798.
16. Ishihara M, Ono K,. Structure and function of heparin and heparan sulfate: Heparinoid library and modification of FGF-activities. Trends Glycosci Glycotech 1998; 10: 223-233.
17. Ishihara M,. Biosynthesis, structure, and biological activity of basic FGF binding domains of heparan sulfate. Trends Glycosci Glycotech 1993; 5: 343-354.
18. Salmivirta M, Lidholt K, Lindahl U,. Heparan sulfate: A piece of information. FASEB J 1996; 10: 1270-1279. (Pubitemid 26307512)
19. Lindahl U, Lidholt K, Spillmann D, Kjellen L,. More to "heparin" than anticoagulation. Thromb Res 1994; 75: 1-32.
20. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE,. Heparin and low-molecular-weight heparin, mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety, Chest 1998; 114: 489S-510S. (Pubitemid 28535777)
21. Wolzt M, Wetermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA,. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin®) at the site of activation of the coagulation system in man. Thromb Haemost 1995; 73: 439-443.
22. Pan M, Lezo JS, Medina A, Romero M, Hernandez E, Segura J, Melian F, Wanguemert F, Landin M, Benitez F, Amat M, Velasco F, Torres A,. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation. Am J Cardiol 1997; 80: 1336-1338. (Pubitemid 27513336)
23. Nakamura S, Kishimoto S, Nakamura S, Nambu M, Fujita M, Tanaka Y, Mori Y, Tagawa M, Maehara T, Ishihara M,. Fragmin/protamine microparticles as cell carriers to enhance viability of adipose-derived stromal cells and their subsequent effect on in vivo neovascularization. J Biomed Mater Res 2010; 92A: 1614-1622.
24. Takikawa M, Nakamura S-I, Nakamura S, Nambu M, Ishihara M, Murakami K, Kishimoto S, Sasaki K, Yanagishita S, Azuma R, Yamamoto N, Kiyosawa T,. Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. J Dermatol Surg 2010; 37: 1-9.
25. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM,. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-670.
26. Tokunaga N, Nagaya N, Shirai M, Tanaka E, Ishibashi-Ueda H, Harada-Shiba M, Kanda M, Ito T, Shimizu W, Tabata Y, Uematsu M, Nishigami K, Sano S, Kangawa K, Mori H,. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: Benefits of a novel nonviral vector, gelatin. Circulation 2004; 109: 526-531. (Pubitemid 38168517)
27. Yamada N, Li W, Ihaya A, Kimura T, Morioka K, Uesaka T, Takamori A, Handa M, Tanabe S, Tanaka K,. Platelet-derived endothelial cell growth factor gene therapy for limb ischemia. J Vasc Surg 2006; 44: 1322-1328. (Pubitemid 44828401)
28. Tang GL, Chang DS, Sarkar R, Wang R, Messina LM,. The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis and inflammation in rat hindlimb ischemia. J Vasc Surg 2005; 41: 312-320. (Pubitemid 40342484)
29. Hopkins SP, Bilgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP,. Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in rabbit model of ischemia. J Vasc Surg 1998; 27: 886-894.
30. Horio T, Fujita M, Tanaka Y, Ishihara M, Kishimoto S, Nakamura S, Hase K, Maehara T,. Efficacy of fragmin/protamine microparticles containing fibroblast growth factor-2 (F/P MPs/FGF-2) to induce collateral vessels in a rabbit model of hindlimb ischemia. J Vasc Surg 2011; 54: 791-798.
31. Morishita R, Nakamura S, Hayashi S-I, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T,. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: 1379-1384. (Pubitemid 29282658)
32. Xu CC, Chan RW, Weinberger DG, Efune G, Pawlowski KS,. Controlled release of hepatocyte growth factor from bovine acellular scaffold for vocal fold reconstruction. J Biomed Mater Res 2010; 93A: 1335-1347.
33. Chen FM, Zhang M, Wu ZF,. Toward delivery of multiple growth factors in tissue engineering. Biomaterials 2010; 31: 6279-6308.